CpG Diagnostics was founded to transform cancer diagnostics through innovative epigenetic technology. We began with a focus on ovarian cancer, the most lethal gynecologic malignancy, where early detection is challenging yet critical for survival.

By licensing groundbreaking technology from leading academic institutions, we've developed a powerful platform that can detect the subtle methylation changes that signal the presence of cancer, offering new hope for earlier and more accurate diagnosis.